Original Agenda
We are actively working with our speakers to confirm their availability for the virtual event. Initial response from our speakers has been very positive, and we are optimistic we will have the new programs ready to share here soon.

Pharmaceutical R&D Informatics

Pharmaceutical R&D departments are at a crossroads – we have more technology and data than ever before, priming us for novel discoveries, yet there are still many challenges informatics strategies must address. The digitalization of the lab is at the forefront, and it necessitates quality data as well as knowledge management strategies, especially in the search for effective, real-world uses of AI and machine learning. We must also address how these new technologies are transforming day-to-day workflow and knowledge exchange, and what change management, investment, and regulatory strategies must be employed to make them successful. The Pharmaceutical R&D Informatics track will explore real-world projects related to digitalization, FAIR data, knowledge management systems, and artificial intelligence development and implementation, and how such initiatives are driving precision medicine.

Final Agenda

Monday, october 5

9:00 am - 5:00 pm Hackathon*

*Pre-registration required.

Tuesday, october 6

7:30 am Workshop Registration Open and Morning Coffee

8:30 am - 3:30 pm Hackathon*

*Pre-registration required.


8:30 - 11:30 am Recommended Morning Pre-Conference Workshops*

W1. Data Management for Biologics: Registration and Beyond Diana Bowley, Business Relationship Manager, Biologics, AbbVie

Benjamin Li, Head of IT RDM Biological Sample Production & Management, Boehringer Ingelheim

Yuan Lin, Senior Manager, Pfizer Digital, Pfizer

Sebastian Schlicker, Director, Biologics Business, Genedata, Basel, Switzerland

Monica Wang, PhD, Principal Bioinformatics Architect, Project and Program Manager, Global Research IT, Takeda

12:30 - 3:30 pm Recommended Afternoon Pre-Conference Workshops*

W9. Digital Biomarkers and Wearables in Pharma R&D and Clinical Trials

Dani Bradnan, MS, Research Associate, Digital Health and Wellness, Lux Research

Ariel Dowling, PhD, Associate Director, Digital Clinical Devices, Data Sciences Institute, Research and Development, Takeda Pharmaceuticals

Graham Jones, PhD, Director, Innovation, Novartis

Larsson Omberg, Vice President, Systems Biology, Sage Bionetworks

*Separate registration required.

2:00 - 6:30 Main Conference Registration Open

PLENARY KEYNOTE SESSION

4:00 Welcome Remarks

Cindy Crowninshield, RDN, LDN, Executive Event Director, Cambridge Healthtech Institute

 

 

 

4:05 Keynote Introduction

4:15 PLENARY KEYNOTE PRESENTATION: NIH’s Strategic Vision for Data Science

Susan K. Gregurick, PhD, Associate Director, Data Science (ADDS) and Director, Office of Data Science Strategy (ODSS), National Institutes of Health

 

 

 

 

Rebecca Baker, PhD, Director, HEAL (Helping to End Addiction Long-term) Initiative, Office of the Director, National Institutes of Health

 

 

 

 

5:00 - 7:00 Welcome Reception in the Exhibit Hall with Poster Viewing

 

 

Wednesday, october 7

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION

8:00 Welcome Remarks

Allison Proffitt, Editorial Director, Bio-IT World

 

 

 

8:05 Awards Program Introduction

J.W. Bizzaro8:10 Benjamin Franklin Award and Laureate Presentation

J.W. Bizzaro, Managing Director, Bioinformatics.org

 

 

 

 

Allison Proffitt8:35 Bio-IT World Innovative Practices Awards

Allison Proffitt, Editorial Director, Bio-IT World

 

 

 

8:45 Keynote Introduction

8:55 PANEL DISCUSSION: Game On: How AI, Citizen Science, and Human Computation Are Facilitating the Next Leap Forward

Seth CooperSeth Cooper, PhD, Assistant Professor, Khoury College of Computer Sciences, Northeastern University

 

 

 

 

 

Lee LancashireLee Lancashire, PhD, Chief Information Officer, Cohen Veterans Bioscience

 

 

 

 

 

Pietro Michelucci, PhD, Director, Human Computation Institute

 

 

 

 

 

Jérôme WaldispühlJérôme Waldispühl, PhD, Associate Professor, School of Computer Science, McGill University

 

 

 

 

 

While the precision medicine movement augurs for better outcomes through targeted prevention and intervention, those ambitions entail a bold new set of data challenges. Various panomic and traditional data streams must be integrated if we are to develop a comprehensive basis for individualized care. However, deriving actionable information requires complex predictive models that depend on the acquisition and integration of patient data on a massive scale. This picture is further complicated by new data streams emerging from quantified self-tracking and health social networks, both of which are driven by experimentation-feedback loops. Tackling these issues may seem insurmountable, but recent advancements in human/AI partnerships and crowdsourcing science adds a new set of capabilities to our analytic toolkit. This talk describes recent work in online collective systems that combine human and machine-based information processing to solve biomedical data problems that have been otherwise intractable, and an information processing ecosystem emerging from this work that could transform the landscape of precision medicine for all stakeholders.

9:45 Coffee Break in the Exhibit Hall with Poster Viewing

ENABLING DIGITAL TRANSFORMATION OF PHARMA R&D

10:50 Organizer’s Welcome Remarks

Cambridge Healthtech Institute

10:55 Chairperson’s Remarks

11:00 Digital Transformation Driving Precision Medicine

Christianson_AnastasiaAnastasia Christianson, Vice President, R&D Business Technology, Janssen Pharmaceuticals

Digital transformation is still a driving principle in pharma R&D with the ultimate goal being to streamline processes and enable precision medicine. This talk will showcase examples of digital technologies driving transformation and tangible results in R&D.

11:30 Enduring Value from Data-Centric Digital Transformation

Vanderwall_DanaDana Vanderwall, PhD, Director, Biology & Preclinical Sciences IT, Research & Development IT, Bristol-Myers Squibb

Companies that have successfully transformed their business demonstrate the necessity of commensurate cultural change. Similarly, our ecosystem must embrace a data-centric design focus to deliver successful digital transformation and enduring value. Without implementing standards to deliver interoperable data with complete, consistent, standard contextual metadata, we will fail to transform the laboratory and data value chain. Continuing to generate data as a by-product of process and software underserves R&D objectives.

12:00 pm Making the Most of Real-WorldData (RWD) with Natural Language Processing (NLP)

Jane Reed, Senior Director, Life Science Strategy, Linguamatics

Real-world data can inform drug use and all phases of drug development/commercialization. Many RWD sources, like electronic health records, patient forums, social media, etc., contain unstructured or semi-structured text. We describe client use cases where Linguamatics NLP transforms RWD to provide visualization or analysis, or feed machine learning models.

12:15 Presentation to be Announced

12:30 Session Break

12:40 Luncheon Presentation I to be Announced

1:10 Luncheon Presentation II (Sponsorship Opportunity Available)

1:40 Session Break

KNOWLEDGE MANAGEMENT AND FAIR DATA DRIVING DECISION-MAKING

1:50 Chairperson’s Remarks

Tom Plasterer, PhD, Director of Bioinformatics, Data Science & AI, Biopharmaceutical R&D, AstraZeneca

1:55 The Essentials of FAIR-ifying Data

Plasterer_TomTom Plasterer, PhD, Director of Bioinformatics, Data Science & AI, Biopharmaceutical R&D, AstraZeneca

While the value of FAIR data has been established–as well as the costs of un-FAIR data–adoption lacks easy routes. The Pistoia Alliance FAIR data toolkit and Innovative Medicines Initiative (IMI) FAIRplus Cookbook offer frameworks to start. Key decisions on what to name things (e.g., identifiers) and their semantics (e.g., vocabularies) are critical at journey inception. Once established, FAIR knowledge graphs and FAIR analytic services become enterprise data-centric enablers.

2:25 How to Hold on to Your Knowledge in an Agile World

Stolte_EtzardEtzard Stolte, PhD, Global Head, Knowledge Management PTD, F. Hoffmann-La Roche

As pharma is embracing digital and agile, new challenges for the retention and sharing of information are emerging. While the information standards of a validated environment remain, ad hoc processes and distributed cloud solutions are creating new islands of knowledge. In this presentation, I will present a knowledge strategy based on automated discovery and integration for a development department of several thousand scientists at Roche.

2:55 Sponsored Presentation (Opportunity Available)

3:25 Refreshment Break in the Exhibit Hall with Poster Viewing

KNOWLEDGE MANAGEMENT AND FAIR DATA DRIVING DECISION-MAKING (CONT.)

4:00 Chairperson’s Remarks

Dana Vanderwall, PhD, Director, Biology & Preclinical Sciences IT, Research & Development IT, Bristol-Myers Squibb

4:05 A Journey to Build an Ecosystem of Data, Technology, and Culture for Insight Generation

Mark McCreary, Biomarker Data Management and Curation Lead (DevSci Informatics), Genentech

We aim to transform drug development and translational sciences by establishing the data and informatics ecosystem. Where do you even start when data are not readily accessible and are constantly evolving? How do you mobilize the organization to change the mindset for data sharing? This talk will share with you the journey we are on to revamp the data management practice and to build the end-to-end engine for FAIRification of our key data assets. We will share the challenges we have overcome and the successes leading to scientific impacts.

4:35 Making Drug Discovery Data FAIR: The Yawning Gap between Aspiration and Implementation

Southan_ChrisChristopher Southan, PhD, Principal Consultant, TW2Informatics

The FAIRification of data is gaining impetus. However, for drug discovery, the envisaged increased flow of structures and bioactivity into major public databases, such as PubChem, has not happened. Reasons will be reviewed, but a key impediment is that even when supplementary data from journal papers is submitted to open repositories, such as figshare, there is neither push nor pull into PubChem. Ways to ameliorate this major bottleneck will be discussed, including bypassing the entombment of chemistry in PDFs.

5:05 Design Hub for Early Phase Drug Discovery

Andras Stracz, Head Developer, Drug Design, Hub Development, ChemAxon

We will introduce ChemAxon’s platform for integration of a variety of data sources and services to augment real-time design. We cover two use cases: 1) how MMP analysis supports design out of hERG liability; and 2) how a search on >500M molecules, from combined public databases, can be analyzed in seconds.

5:20 Sponsored Presentation (Opportunity Available)

 

RedRiver

5:35 Best of Show Awards Reception in the Exhibit Hall with Poster Viewing

 

6:45 End of Day

Thursday, october 8

7:30 am Registration Open and Morning Coffee

PLENARY KEYNOTE SESSION & AWARDS PROGRAM

8:00 Organizer’s Remarks

Cindy Crowninshield, RDN, LDN, Executive Event Director, Cambridge Healthtech Institute

 

 

 

Robert Green8:15 Toward Preventive Genomics: Lessons from MedSeq and BabySeq

Robert Green, MD, MPH, Professor of Medicine (Genetics) and Director, G2P Research Program/Preventive Genomics Clinic, Brigham & Women’s Hospital, Broad Institute, and Harvard Medical School

 

 

 

Natalija Jovanovic9:00 AI in Pharma: Where We Are Today and How We Will Succeed in the Future

Natalija Jovanovic, PhD, Chief Digital Officer, Sanofi Pasteur

 

 

 

9:45 Coffee Break in the Exhibit Hall and Poster Competition Winners Announced at 10:00

 

 

EXPLORATION TOOLS FOR DRUG DISCOVERY AND DEVELOPMENT

10:30 Organizer’s Remarks

Cambridge Healthtech Institute

10:35 Chairperson’s Remarks

10:40 Powering Question-Driven Problem Solving to Improve the Chances of Finding New Medicines**

Hasan_SamiulSamiul Hasan, PhD, Scientific Analytics and Visualization Director, Data and Computational Sciences, GlaxoSmithKline

Making true “molecule”-“mechanism”-“observation” relationship connections is a time-consuming, iterative and laborious process. In addition, it is very easy to miss critical information that affects key decisions or helps make plausible scientific connections. The current practice for deciphering such relationships frequently involves subject matter experts (SMEs) requesting resources from resource-constrained data science departments to refine and redo highly similar ad hoc searches. The result of this is impairment of both the pace and quality of scientific reviews. In this presentation, I show how semantic integration can be made to ultimately become part of an integrated learning framework for more informed scientific decision-making. I will take the audience through our pilot journey and highlight practical learnings that should inform subsequent endeavors.

11:10 Computational Efforts on Drug Repurposing for Rare Diseases

Li_BinBin Li, PhD, Director, Computational Biology, Takeda Pharmaceutics

We conducted in silico screens trying to repurpose >100 compounds for ~4000 rare disease indications. Various data types were utilized (protein-protein interaction network, pathways, disease-driven genes, competitive intelligence, etc), and different computational methods were implemented and evaluated. Some biologically interesting drug/disease pairs were observed.

11:40 Presentation to be Announced

 

12:10 pm Session Break

Deloitte_ConvergeHealth 12:20 Luncheon Presentation I to be Announced

 

Schrodinger 12:50 Luncheon Presentation II

 

1:20 Dessert Refreshment Break in the Exhibit Hall with Last Chance Poster Viewing

USING AI TO PROPEL THE DRUG DISCOVERY AND DEVELOPMENT PIPELINE

1:55 Chairperson’s Remarks

Bino John, PhD, Associate Director, Data Science – Clinical Pharmacology & Safety Sciences, AstraZeneca R&D


2:00 KEYNOTE PRESENTATION: Accelerated Drug Development Using AI

John_BinoBino John, PhD, Associate Director, Data Science – Clinical Pharmacology & Safety Sciences, AstraZeneca R&D

Drug development is an expensive and costly endeavor, costing on an average of 2.6 billion dollars to bring a drug to market. Data science and artificial intelligence are essential in reducing the costs and time to bring these to the clinic. This talk will highlight some of the current initiatives in analytics at AstraZeneca, spanning chemical and biological data. The talk will provide specific use cases in which we use AI to improve drug design and develop safer medicines.

2:30 Real-World Data and AI Hype: Stimulating and Supporting Each Other

Bartels_DorotheeDorothee Bartels, PhD, Clinical and Real World Data Strategy Lead, X, Alphabet

The real-world data hype caused high expectations, including RCTs only playing a minor role in future drug development, when in fact, they are complementary to RCT data and cannot replace them. Artificial intelligence may change drug development and time to market significantly, but will not replace past knowledge and experience. Real-World Evidence generation can be enhanced by AI and is key for public health.

3:00 Machine-Learned Molecular Models for Protein Structure, Networks, and Design

AlQuraishi_MohammedMohammed AlQuraishi, PhD, Systems Biology Fellow, Harvard Medical School


3:30 Mining Drug-Target-Disease Trends from Public Data Sources

Henstock_PeterPeter Henstock, PhD, AI & Machine Learning Technical Lead, Pfizer


4:00 Close of Conference

 



Platinum Sponsors

accenture

BenchlingNEW

Elsevier-square

L7-informatics

linguamatics

Nutanix

PerkinElmer

Weka_Purple